Research & Development
The iQ Group Global acquires new TEX-Core anticancer drug platform from University of Texas
17 September 2019 -

Bioscience discoveries company The iQ Group Global reported on Monday the completion of the acquisition of a novel anticancer drug platform TEX-Core from the University of Texas to develop a range of cancer therapeutics.

The company said TEX-Core is an anticancer drug platform that has the ability to develop a range of well-tolerated, MRI-detectable cancer therapeutics that target drug-sensitive and drug-resistant solid tumours. ­

Following the acquisition, the first cancer therapeutic to be commercialized from the The iQ's platform is OxaliTEX, a novel chemical entity that targets only solid tumor cells, activates within the tumour and overcomes drug-resistance mechanisms with minimal side effects.

TEX-Core researchers and inventors and the MD Anderson Cancer Center are to commence clinical trials in the next 12 months. The iQ Group plans to develop OxaliTEX through an orphan drug designation in ovarian cancer, utilizing an expedited FDA approval pathway.

Currently, 50% of all chemotherapy patients are treated with platinum-based chemotherapy, which are known for extreme side effects, which means doses must be limited. In addition, patients often present with platinum resistance, which makes the treatment ineffective.

Login
Username:

Password: